SunTrust Banks Weighs in on Galmed Pharmaceuticals Ltd’s FY2022 Earnings (GLMD)
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) – SunTrust Banks issued their FY2022 earnings per share estimates for Galmed Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the year.
Several other equities research analysts have also commented on the company. Roth Capital initiated coverage on Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $32.00 price objective for the company. Maxim Group set a $14.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Wednesday, January 10th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $20.40.
Several large investors have recently bought and sold shares of the company. 683 Capital Management LLC increased its stake in shares of Galmed Pharmaceuticals by 18.2% in the 4th quarter. 683 Capital Management LLC now owns 649,295 shares of the biopharmaceutical company’s stock worth $5,941,000 after purchasing an additional 100,000 shares in the last quarter. Meitav Dash Investments Ltd. purchased a new stake in Galmed Pharmaceuticals in the 4th quarter worth $4,357,000. Park West Asset Management LLC increased its stake in Galmed Pharmaceuticals by 4.4% in the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock worth $2,679,000 after buying an additional 12,347 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in Galmed Pharmaceuticals in the 4th quarter worth $2,164,000. Finally, J. Goldman & Co LP purchased a new stake in Galmed Pharmaceuticals in the 4th quarter worth $569,000. Hedge funds and other institutional investors own 11.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “SunTrust Banks Weighs in on Galmed Pharmaceuticals Ltd’s FY2022 Earnings (GLMD)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://theolympiareport.com/2018/02/21/suntrust-banks-weighs-in-on-galmed-pharmaceuticals-ltds-fy2022-earnings-glmd.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.